Next-generation AAV vectors for liver-directed gene therapybroad
AAVolution · Horizon Europe grant · 2022-10-01–2027-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2021-PATHFINDERCHALLENGES-01-03. CORDIS record →
Objective
Liver-directed gene therapy has undergone significant development in the last two decades. Recombinant adeno-associated vectors (AAV) are the vectors of choice for liver gene transfer and have recently achieved remarkable successes in clinical trials. However, there are still large groups of patients who have limited access to therapy. The major hurdles toward expanding the indication of AAV-mediated liver gene therapy are: i) transient AAV-mediated expression in proliferating hepatocytes, i.e. newborn or regenerating livers, due to dilution of episomal AAV genome in proliferating cells; ii) dose-dependent hepatotoxicity and immune response against AAVs; and iii) pre-existing immunity to AAV capsids, which currently preclude its systemic delivery in about 50% of individuals. AAVolution gathers renowned European experts in the field of AAV vectorology, gene therapy, genome editing and immunology, with the ambitious goal to develop and implement innovative therapeutic tools to effectively address these challenges. To this aim AAVolution proposes: i) to seek novel small Cas nucleases for in vivo AAV-mediated genome editing ii)to develop self-replicating episomal AAVs to avoid transgene dilution in proliferating livers; iii) to generate synthetic AAVs characterized by enhanced potency and reduced toxicity, by screening of novel AAV capsid libraries; iv) and to develop improved technologies to overcome pre-existing immunity to AAVs by transiently reducing the levels of circulating anti-AAV neutralizing antibodies.AAVolution will significantly expand the toolkit for AAV-mediated liver gene therapy, developing novel and improved molecular instruments to address the most relevant hurdles toward safer and more effective therapies, and provide access to treatment to patients that are currently excluded from clinical trials. Moreover, these novel tools will constitute an innovative platform with a potential for broad expansion of disease indications beyond the rare diseases.
Beneficiaries (10)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| FONDAZIONE TELETHON ETS | IT | coordinator | €1,384,642 | |
| ASSOCIATION GENETHON | FR | participant | €591,000 | |
| UNIVERSITA DEGLI STUDI DI TRENTO | IT | participant | €551,600 | |
| FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA | ES | participant | €551,600 | |
| MEDIZINISCHE HOCHSCHULE HANNOVER | DE | participant | €512,200 | |
| ALLATORVOSTUDOMANYI KUTATOINTEZET | HU | participant | €450,000 | |
| UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II | IT | participant | €394,000 | |
| CINFERENCE GMBH | DE | participant | €64,958 | Yes |
| INNOVAVECTOR SRL | IT | thirdParty | €0 | Yes |
| NEXT GENERATION DIAGNOSTIC SRL | IT | thirdParty | €0 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.